Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Authors
Ning Li
Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, China
Ning Li , Zhi Li , Qiang Fu , Bin Zhang , Jian Zhang , XiangBin Wan , Chaomin Lu , Jinbang Wang , Wenying Deng , Chen Wei , Yijie Ma , Liangyu Bie , Mengyu Wang , SuXia Luo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03950271
DOI
10.1200/JCO.2022.40.4_suppl.296
Abstract #
296
Poster Bd #
L5
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Short-course radiotherapy and subsequent CAPOX plus camrelizumab followed by delayed surgery for locally advanced rectal cancer: Short-term results of a phase II trial.
First Author: Zhenyu Lin
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Ning Li
Poster
2021 ASCO Annual Meeting
Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Hongli Li
Poster
2021 Gastrointestinal Cancers Symposium
Sintilimab plus oxaliplatin/capecitabine (CapeOx) as neoadjuvant therapy in patients with locally advanced, resectable gastric (G)/esophagogastric junction (GEJ) adenocarcinoma.
First Author: Haiping Jiang